Equity Offerings

Apricus Biosciences, Inc. (Nasdaq: APRI) announced that it has priced an underwritten public offering of an aggregate of 6,000,000 shares of common stock at a price to the public of $2.85 per share, and warrants to purchase up to an aggregate of 3,000,000 shares of common stock for gross offering proceeds of $17,100,000. The shares of common stock and warrants are immediately separable and will be issued separately. The warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $3.40 per share. The warrants will be certificated, and will be delivered to the investors by physical delivery following the closing. There is no established public trading market for the warrants and we do not expect a market to develop. Certain officers and directors of the Company have also participated in the offering and will be purchasing the offered securities from the underwriters.

In addition, Apricus Bio has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock and warrants to purchase up to an additional 450,000 shares of common stock to cover over-allotments, if any. The net offering proceeds to Apricus Bio from this offering are expected to be approximately $15.8 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding the exercise of any warrants and any exercise of the underwriters' over-allotment option. The offering is expected to close on or about May 29, 2013, subject to customary closing conditions.

Lazard Capital Markets LLC is acting as sole book-running manager for the offering and Roth Capital Partners, LLC and Cantor Fitzgerald & Co. are acting as co-managers for the offering.

Chemical Financial Corp (Nasdaq: CHFC) filed a registration with the U.S. SEC to sell, from time to time, up to $100 million of Common Stock, Preferred Stock, Debt Securities, Depositary Shares, Warrants, Purchase Contracts, Units, or any combination thereof.

Bloomin' Brands, Inc. (the "Company") (Nasdaq: BLMN) announced the pricing of a secondary public offering of 19,000,000 shares of the Company's common stock at a price of $21.50 per share. All of the shares are being offered by certain stockholders of the Company. The offering is expected to close on May 29, 2013, subject to the satisfaction of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 2,850,000 shares of common stock from certain selling stockholders.

The offering is being made through an underwriting group led by BofA Merrill Lynch, Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Deutsche Bank Securities Inc., and Goldman, Sachs & Co. who are acting as joint book-running managers. Jefferies LLC is acting as co-lead manager of the offering. William Blair & Company, L.L.C., Raymond James & Associates, Inc, Wells Fargo Securities, LLC, and The Williams Capital Group, L.P. are acting as co-managers of the offering.

Blackstone Mortgage Trust (NYSE: BXMT) announced the pricing of an underwritten public offering of 22,500,000 shares of its class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission at a public offering price of $25.50 per share. The offering was upsized from 16,000,000 shares to 22,500,000 shares. The offering is expected to close on May 29, 2013 and is subject to customary closing conditions. The offering will generate gross proceeds of approximately $573.8 million, or $659.8 million if the underwriters exercise their option to purchase additional shares in full.

The price is up from 16 million shares originally offered.

The Company intends to use the proceeds from the offering to originate and acquire an initial portfolio of senior mortgage loans and pari passu participations in existing senior mortgage loans, to originate and acquire additional commercial real estate loans in the United States and Europe, and for working capital and general corporate purposes.

Citigroup, BofA Merrill Lynch, J.P. Morgan, Deutsche Bank Securities, Wells Fargo Securities and UBS Investment Bank are acting as joint book-running managers for the offering. Blackstone Capital Markets, Keefe, Bruyette & Woods A Stifel Company, Evercore Partners and JMP Securities are acting as co-managers. The underwriters have been granted a 30-day option by the Company to purchase up to an additional 3,375,000 shares at the public offering price, less the underwriting discounts and commissions.

Apricus Biosciences, Inc. (Nasdaq: APRI) is trading down 18 percent after-hours Wednesday after the company announced that it intends to offer shares of common stock and warrants in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock and warrants to cover over-allotments, if any.

Lazard Capital Markets LLC is acting as sole book-running manager for the offering.